RxDoctor Payments Data

Rebecca Blank, PA

Medical · Onalaska, WINPI 1518961333

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,450 of the $31,173 with a category attached, or 91.3%. AstraZeneca accounts for 99.5% of it on its own, with 2 other manufacturers making up the rest. Among medical clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,173in general payments, 2019–2025

Across 53 payments — averaging $588.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$31K
  • Verona Pharma, Inc.$125
  • Stryker$15

What the payments were for

  • Speaking & faculty fees$28,45091%
  • Travel & lodging$1,1174%
  • Food & beverage$1,6065%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca51$31,032
Verona Pharma, Inc.1$125
Stryker1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,173 in reported general payments places this provider in the 95th percentile of 247 medical providers in Wisconsin.

See all medical providers in Wisconsin

Medicare billing

Part B allowed, 2024
$19,923
Medicare patients
223
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter533$410,113
Breztri AerosphereBudesonide/Glycopyr/Formoterol182$130,569
Breo ElliptaFluticasone/Vilanterol107$49,331
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr78$38,344
Spiriva RespimatTiotropium Bromide33$21,665
Incruse ElliptaUmeclidinium Bromide43$21,507
Arnuity ElliptaFluticasone Furoate91$21,424
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate50$13,768
Fluticasone-SalmeterolFluticasone Propion/Salmeterol101$12,817
Albuterol Sulfate HfaAlbuterol Sulfate321$12,812
Fluticasone Propionate HfaFluticasone Propionate32$12,518
Advair HfaFluticasone Propion/Salmeterol26$11,103
SymbicortBudesonide/Formoterol Fumarate26$7,384
BreynaBudesonide/Formoterol Fumarate45$6,748
Ventolin HfaAlbuterol Sulfate35$3,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort$31,032$137,953208 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 medical providers in Wisconsin.

Other medical in Onalaska

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →